star born aimovig
anoth beat rais
report revenu consensu adjust ep
beat consensu product sale reduc sg expens
rais full year guidanc yet revenu
adjust ep continu share repurchas program
buy back commit anoth adjust
non-gaap ep accordingli maintain multipl
in-lin major biopharma peer reiter buy strong fundament
despit quarter-over-quart declin repatha sale due net price impact
top-line still manag beat consensu expect driven solid perform
across board largest contributor beat enbrel sale
epogen sale neulasta sale notabl met even slightli beat
consensu despit declin revenu lower net sell price biosimilar
impact impact could howev becom pronounc potenti
second biosimilar year-end prolia xgeva miss consensu continu
achiev doubl digit growth remain signific driver amgn top-line
consensu notabl patient start aimovig sinc launch
prescrib base parsabiv launch solid convert
market ahead potenti gener sensipar entri launch said gener dictat
amgn abil meet top end revenu guidanc
pipelin catalyst year-end
number pipelin asset report data rest year includ
ns bcma bite bite show data
american societi hematolog annual meet decemb amgn phase
studi antibodi migrain prevent expect
readout result year-end medic meet present
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biopharmaceut compani
develop manufactur market biolog
therapi oncolog inflamm
five key market product among top
sell pharmaceut product world
collect revenu
buy rate base new product launch
anticip biosimilar launch
help drive top-lin growth strong
cash posit also allow addit share
buyback dividend payment transform
price object base multipl ep estim
non-gaap ep exclud stock option expens amort intang asset
restructur charg non-cash expens multipl support
strong cash flow gener dividend payout choic multipl
line major pharma peer
downsid risk po greater-than-forecast declin esa neupo
enbrel revenu greater-than-expect price pressur europ potenti drug
price system restructur us failur bring new pipelin product
upsid risk po less-than-forecast declin key product revenu
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
